3 chapters across the catalog
Ozempic, a diabetes medication containing semaglutide, has become a viral weight-loss sensation on TikTok and in Hollywood. Manufacturer Novo Nordisk maintains that the drug is not intended for off-label weight loss, though the FDA allows doctors to prescribe it as they see fit. The hosts note that while the drug is marketed heavily to white women in media, black communities are also being targeted using cultural terms like "sugar" for diabetes.
New testimonials suggest that semaglutide drugs like Ozempic may inadvertently cure other addictions, including alcoholism, vaping, and gambling. This has caused concern in the alcohol and tobacco industries, with Walmart reporting a slight decrease in snack sales. The hosts discuss the potential for a "drug war" between pharmaceutical companies and traditional vice industries as consumer habits shift.
The segment recalls the 1997 recall of the diet drug Fen-Phen due to fatal heart valve complications. The hosts compare this history to the current Ozempic craze, noting that Pfizer's stock dropped after its own weight-loss pill failed clinical trials. They suggest that American pharmaceutical giants may eventually target Novo Nordisk's market dominance by highlighting safety concerns.
